Completed Enrollment

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

Trial Summary

Age Range
≥40 years
Conditions the trial is for
Obesity
What the trial is testing?
Tirzepatide
Could I receive a Placebo?
Yes
Enrollment Goal
15374
Trial Dates
Oct 11, 2022 - Oct 2027
How long will I be in the trial?
The study will last about 5 years and include up to 30 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be overweight or have obesity

  • Are over age 40 and have heart disease at least 3 months before study start

  • Women at least 55 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, kidney disease, or high sugar levels.

  • Men at least 50 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, kidney disease, or high sugar levels.

Participants Must Not:

  • Have type 1 diabetes or type 2 diabetes at the beginning of the study

  • Have any of the cardiovascular conditions such as: heart attack, stroke, procedure to treat coronary artery disease, or heart failure requiring IV medication or left ventricular assist device. 3 months before the start of the study

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources